ABBV News & Events

The company said, "This morning, we announced the termination of our development agreement with AbbVie. While this represents the close of an important chapter, we see it as the beginning of an even more promising journey. I'd like to share our vision for what lies ahead for CollPlant in 2026. As noted, Allergan Industrie SAS, an AbbVie company, notified us that it was exercising its right to terminate the development agreement, previously entered into in February 2021, upon 60 days' advance notice. During the prior five years, AbbVie was developing a dermal and soft tissue filler product for commercialization in the medical aesthetics market, using the Company's rhCollagen technology. We view this development as an opportunity, and we are moving forward with confidence. Interest in CollPlant's collagen technology remains strong and we are actively pursuing entering into agreements with new partners, across all types of aesthetic products, including for dermal and soft tissue filler products. The market opportunity before us is significant, and we intend to capture it. Over the past few months, we have engaged with several leading strategic partners and Tier 1 corporations to explore potential joint development opportunities, primarily in the aesthetics sector. These collaborations focus on dermal filler products incorporating CollPlant's technology, hyaluronic acid, and other key components. While these discussions naturally take time, we are actively working to accelerate the process and, while there is no guarantee, are optimistic about reaching a definitive agreement in the coming months."

AbbVie announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology, SGO, Annual Meeting. The study evaluated the potential efficacy and safety of mirvetuximab soravtansine-gynx, Elahere, in combination with carboplatin followed by maintenance of mirvetuximab soravtansine-gynx monotherapy, in patients with folate receptor alpha-expressing, recurrent platinum-sensitive ovarian cancer, PSOC. The multicenter, open-label study enrolled 125 patients with FRalpha-positive, measurable disease who had received one prior platinum-based chemotherapy regimen. The primary endpoint of the study was a confirmed objective response rate in the greater than or equal to50% FRalpha subgroup after six cycles of combination therapy. Key secondary endpoint was ORR after six cycles in the overall population and additional secondary endpoints included duration of response, progression-free survival and overall survival.